Lipocine Inc. Files Q2 2024 10-Q
Ticker: LPCN · Form: 10-Q · Filed: 2024-08-08T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Lipocine Inc. Q2 10-Q filed. Financials and ops update.
AI Summary
Lipocine Inc. filed its 10-Q for the period ending June 30, 2024. The filing covers financial performance and operational updates for the second quarter of 2024. Key financial data and disclosures relevant to investors are included.
Why It Matters
This filing provides investors with the latest financial health and operational status of Lipocine Inc., crucial for understanding the company's performance and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Lipocine Inc. faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-06-30 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2024-08-08 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Lipocine Inc. (company) — Filer of the 10-Q
- 20240630 (date) — End of the reporting period
- 20240808 (date) — Filing date
- SALT LAKE CITY (location) — Business and mailing address city
FAQ
What is the primary business of Lipocine Inc.?
Lipocine Inc. is primarily involved in the pharmaceutical preparations industry, as indicated by its SIC code [2834].
What is the fiscal year end for Lipocine Inc.?
Lipocine Inc.'s fiscal year ends on December 31st.
What is the SEC file number for Lipocine Inc.?
The SEC file number for Lipocine Inc. is 001-36357.
What is the business address of Lipocine Inc.?
The business address of Lipocine Inc. is 675 Arapeen Drive, Suite 202, Salt Lake City, UT 84108.
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending June 30, 2024.
From the Filing
0001493152-24-030648.txt : 20240808 0001493152-24-030648.hdr.sgml : 20240808 20240808061903 ACCESSION NUMBER: 0001493152-24-030648 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240808 DATE AS OF CHANGE: 20240808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 241185865 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 10-Q 1 form10-q.htm false Q2 --12-31 0001535955 P10Y 0001535955 2024-01-01 2024-06-30 0001535955 2024-08-08 0001535955 2024-06-30 0001535955 2023-12-31 0001535955 2024-04-01 2024-06-30 0001535955 2023-04-01 2023-06-30 0001535955 2023-01-01 2023-06-30 0001535955 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-03-31 0001535955 us-gaap:CommonStockMember 2023-03-31 0001535955 us-gaap:TreasuryStockCommonMember 2023-03-31 0001535955 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001535955 us-gaap:RetainedEarningsMember 2023-03-31 0001535955 2023-03-31 0001535955 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-04-01 2023-06-30 0001535955 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001535955 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001535955 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001535955 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001535955 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-06-30 0001535955 us-gaap:CommonStockMember 2023-06-30 0001535955 us-gaap:TreasuryStockCommonMember 2023-06-30 0001535955 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001535955 us-gaap:RetainedEarningsMember 2023-06-30 0001535955 2023-06-30 0001535955 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001535955 us-gaap:CommonStockMember 2022-12-31 0001535955 us-gaap:TreasuryStockCommonMember 2022-12-31 0001535955 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001535955 us-gaap:RetainedEarningsMember 2022-12-31 0001535955 2022-12-31 0001535955 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-06-30 0001535955 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001535955 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-06-30 0001535955 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001535955 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001535955 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-03-31 0001535955 us-gaap:CommonStockMember 2024-03-31 0001535955 us-gaap:TreasuryStockCommonMember 2024-03-31 0001535955 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001535955 us-gaap:RetainedEarningsMember 2024-03-31 0001535955 2024-03-31 0001535955 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-04-01 2024-06-30 0001535955 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001535955 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001535955 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001535955 us-gaap:Ac